Amyntas Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -27.27%
- Ebitda -27.27%
- Net Worth -13.49%
- Total Assets -8.89%
About Amyntas Pharma
Amyntas Pharma Private Limited (APPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 14 February 2017 (Seven years and 11 months 27 days old ). Its registered office is in Aurangabad, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sajjadali Syed, Apoorva Shedge, and Harshal Patil serve as directors at the Company.
Company Details
-
Location
Aurangabad, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U33302MH2017PTC291193
-
Company No.
291193
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Feb 2017
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Amyntas Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sajjadali Syed
|
Director | 19-Sep-2024 | Current |
|
Apoorva Shedge
|
Director | 19-Sep-2024 | Current |
|
Harshal Patil
|
Director | 19-Sep-2024 | Current |
Financial Performance of Amyntas Pharma.
Amyntas Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 27.27% decrease in profit. The company's net worth observed a substantial decline by a decrease of 13.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amyntas Pharma?
In 2020, Amyntas Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Biovion Pharma Private LimitedSajjadali Syed and Harshal Patil are mutual person
-
Genmeds Private Limited
Sajjadali Syed is a mutual person
-
Virtus Security Services Private Limited
Apoorva Shedge is a mutual person
-
Virtus Hospitality Private Limited
Apoorva Shedge is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Amyntas Pharma?
Unlock and access historical data on people associated with Amyntas Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amyntas Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amyntas Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
